Bleeding events and maintenance dose of prasugrel: BLESS pilot study. Issue 2 (31st October 2016)

• Record Type: Journal Article
• Authors: Carrabba, Nazario; Parodi, Guido; Marcucci, Rossella; Valenti, Renato; Gori, Anna Maria; Migliorini, Angela; Comito, Vincenzo; Bellandi, Benedetta; Abbate, Rosanna; Gensini, Gian Franco; Antoniucci, David
• Is Part Of: Open heart. Volume 3:Issue 2(2016)
• Publication Date: 2016-10-31
• Subjects: PHARMACOLOGY -- PERCUTANEOUS CORONARY INTERVENTION; Cardiology -- Periodicals; Heart -- Diseases -- Periodicals; Heart -- Diseases -- Patients -- Periodicals; 616.12005
• DOI: 10.1136/openhrt-2016-000460
• Languages: English
• ISSNs: 2398-595X

Abstract

Abstract : Objective: To evaluate changes in residual platelet reactivity (RPR) over time, and bleeding and ischaemic events rate using 5 vs 10 mg maintenance dose (MD) regimens of prasugrel 1 month after acute coronary syndrome (ACS). Background: The optimal level of RPR with prasugrel may change over time after an ACS. Methods: After 60 mg loading dose of prasugrel (T0) followed by 10 mg/day for 1 month, patients were randomised to receive prasugrel 10 mg/day (n=95, group A) or 5 mg/day MD (n=98, group B) up to 1 year. RPR was assessed at T0, 37 (T1) and 180 days (T2). The primary end point was Bleeding Academic Research Consortium (BARC) bleeding events ≥2 between 1 and 12 months, and the secondary composite end point was cardiac death, myocardial infarction, stroke and definite/probable stent thrombosis. Results: From T0 to T1, RPR significantly increased in both groups A and B and the increase was higher for group B (δ ADP 10 µmol: 13.8%±14.7% vs 23.5%±19.2%, p=0.001). At T2 a lower rate of high RPR patients were found in group A (2.6% vs13.3%; p=0.014). The BARC type ≥2 bleeding occurred in 12.6% of group A versus 4.1% of group B (OR 0.29, 95% CI 0.09 to 0.94) and secondary end point in 2.1% vs 1.0% (p=0.542), respectively, without stent thrombosis. Conclusions: RPR increases shifting from 60 mg loading dose to 10 mg/day prasugrel MD with a further increase of RPR reducing prasugrel MD to 5 mg 1 month after ACS. Clinical value of these pharmacodynamic findings should be proved in larger clinical trials. Trial registration number: NCT01790854.